Clinical trials
First-Line clinical trials
Below are recruiting first-line clinical trials, each written for real people, not researchers. We’re tracking 399 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06282445RecruitingPhase 2
Combination therapy for first-line metastatic colorectal cancer
This trial tests whether adding the immunotherapy drug adebrelimab to standard chemotherapy plus bevacizumab can help people with a specific type of metastatic colorectal cancer that cannot be removed by surgery. It is for patients whose tumors are microsatellite stable (MSS) or have normal mismatch repair (pMMR).
Jinhua, ZhejiangAges 18–75 - NCT07389265RecruitingPhase 3
Continuing cetuximab after first treatment stops working for metastatic colorectal cancer
This trial tests if continuing the targeted therapy cetuximab after initial treatment stops working can help people with advanced colorectal cancer. Participants have a specific gene profile (RAS and BRAF normal) and their cancer responds well at first.
AnconaAges 18 years+ - NCT07391618RecruitingPhase 2
First treatment for advanced colorectal cancer with combo chemo
This trial tests a combination of two chemotherapy drugs, levozolinate and 5-FU, given together as a first treatment for advanced colorectal cancer that cannot be surgically removed. It aims to see if giving them at the same time works better for patients who have never received treatment for this stage of cancer.
BeijingAges 18–75 - NCT06832267Recruiting
RMTT chemo for newly diagnosed PCNS lymphoma
This trial tests a combination of four chemotherapy drugs (Rituximab, Methotrexate, Temozolomide, and Thiotepa) as the first treatment for people newly diagnosed with primary central nervous system diffuse large B-cell lymphoma. It aims to see if this regimen is safe and effective for patients who have not had any prior systemic therapy.
Hangzhou, ZhejiangAges 18–75 - NCT06405113RecruitingPhase 2
Fecal transplant, chemo, and immunotherapy for advanced stomach cancer
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
ChangzhouAges 18–80 - NCT07371585RecruitingPhase 2
Trastuzumab Deruxtecan for first-line HER2-positive advanced breast cancer
This trial tests a targeted therapy called Trastuzumab Deruxtecan (T-DXd) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those who have not yet received any chemotherapy or HER2-targeted treatment for metastatic disease. The study also focuses on managing side effects early, using digital tools to track symptoms.
VillejuifAges 18 years+ - NCT07373964RecruitingPhase 2
Study of new drug combo for extensive-stage small-cell lung cancer
This trial tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if this combination works better than standard treatments.
Shenyang, LiaoningAges 18–75 - NCT06670911RecruitingPhase 2
Lower dose pembrolizumab with chemo for advanced cervical cancer
This trial tests a lower dose of pembrolizumab combined with standard chemotherapy as a first treatment for cervical cancer that has spread, come back, or cannot be removed by surgery. The goal is to see if this combination can help shrink tumors and slow the cancer's growth.
Rio de Janeiro, Rio de JaneiroAges 18 years+ - NCT06743945RecruitingPhase 2
Study of polatuzumab, rituximab, CHP for transformed DLBCL
This trial tests a combination of drugs (POLA-R-CHP) as a first treatment for patients whose large B-cell lymphoma has changed from a slower-growing type. It aims to see if this therapy is effective and safe for newly diagnosed patients.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07362459RecruitingPhase 3
Study of SCTB14 for untreated advanced non-small cell lung cancer
This trial tests a new drug, SCTB14, as a first treatment for advanced non-small cell lung cancer that has a high level of PD-L1. It aims to see if the drug is safe and effective for people who haven't had other treatments for their cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06763029RecruitingPhase 2
Study of three drugs for advanced colorectal cancer after first treatment
This trial tests a combination of three drugs (irinotecan liposomes, cetuximab, and vemurafenib) for people with advanced colorectal cancer that has a specific genetic change (BRAF V600E mutation) and did not respond to first treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07355205RecruitingPhase 1/Phase 2
Combination immunotherapy for advanced lung cancer
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
St Louis, MissouriAges 18 years+ - NCT07353840Recruiting
Personalized treatment for T-cell lymphoma after first complete remission
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06700590Recruiting
Intensive PTSD treatment for first-time patients
This study tests an intensive treatment program for adults with PTSD from multiple traumatic events. It may help if you are seeking treatment for the first time and are currently employed or on sick leave for less than two years.
Diemen, North HollandAges 18 years+ - NCT07340723RecruitingPhase 2
New treatment study for grade II acute GVHD after transplant
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07339878Recruiting
Choosing the first treatment for advanced bladder cancer
This study looks at the different ways doctors choose the first treatment for patients whose urothelial cancer has spread. It aims to understand what factors influence that choice, which could help improve care for future patients.
StrasbourgAges 18 years+ - NCT06863857Recruiting
CT Scan to Check Response to First Kidney Cancer Treatment
This study uses a special CT scan to see how well your first treatment for kidney cancer that has spread is working. It looks at people with clear cell renal cell carcinoma who are starting immunotherapy combined with a targeted drug or two immunotherapy drugs.
Bologna, BOAges 18 years+ - NCT07316686RecruitingPhase 1
Study of docetaxel and lutetium-PSMA for first-line treatment of metastatic prostate cancer
This trial tests a combination of chemotherapy (docetaxel) and a targeted radiation therapy (lutetium-PSMA) as a first treatment for men whose prostate cancer has spread and no longer responds to hormone therapy. The goal is to see if this combination is safe and effective.
São PauloAges 18 years+ - NCT07309289RecruitingPhase 3
Comparing two drug combos for first-line metastatic colorectal cancer
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.
ShanghaiAges 18 years+ - NCT07311408RecruitingPhase 2
New drug combo for stomach cancer after immunotherapy
This trial tests a combination of new drugs (SHR-1701, Rivoceranib, and possibly SHR-2554) for people with advanced stomach cancer whose disease has continued to grow after immunotherapy. It aims to find a better treatment option for those who have not had success with standard therapy.
Shenyang, LiaoningAges 18 years+ - NCT07309185RecruitingPhase 2
Adebrelimab, famitinib, and irinotecan for advanced stomach cancer
This trial tests a combination of three drugs (adebrelimab, famitinib, and irinotecan) for people with advanced stomach or gastroesophageal junction cancer that got worse after first-line treatment. It may offer a new option if you have already tried standard therapy.
Jinan, ShandongAges 18–75 - NCT07311577RecruitingPhase 2
Trial of a drug combo for HER2-positive ovarian cancer
This trial tests a combination of disitamab vedotin, platinum chemotherapy, and bevacizumab as first treatment for high-risk ovarian cancer that has a protein called HER2. The goal is to see if this therapy helps control the cancer and keeps it from growing.
Nanjing, JiangsuAges 18–75 - NCT06521866RecruitingPhase 2
Study of serplulimab plus standard therapy for advanced colorectal cancer
This trial tests an immunotherapy drug (serplulimab) combined with targeted therapy, chemo, and radiation as a first treatment for people with advanced colorectal cancer that has spread and cannot be surgically removed. It aims to see if this combination can help control the cancer.
Fuzhou, FujianAges 18 years+ - NCT07306286RecruitingPhase 2
Cryoablation plus immunotherapy for advanced pancreatic cancer
This trial tests combining cryoablation (freezing tumors) with a dual-antibody drug (PD-1/CTLA-4) for people whose locally advanced pancreatic cancer has stopped responding to first-line chemotherapy (AG regimen). The goal is to see if this combination can help control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new First-Line trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for first-line?
- Yes. Clin2 currently lists 399 recruiting first-line studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a first-line trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a first-line trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.